New challenges to medicare beneficiary access to mAbs.
Precision binding of monoclonal antibodies (mAbs) to biological targets, their relative clinical success, and expansion of indications following initial approval, are distinctive clinical features. The relatively high cost of mAbs, together with the absence of a regulatory pathway to generics, stand out as distinctive economic features. Based on both literature review and primary data collection we enumerated mAb original approvals, supplemental indications and off-label uses, assessed payer formulary management of mAbs, and determined new challenges to Medicare beneficiary access to mAbs. We found that the FDA has approved 22 mAbs and 30 supplemental indications pertaining to the originally approved mAbs. In addition, there are 46 off-label use citations in officially recognized pharmaceutical compendia. Across Part B carriers and Part D plans, we found considerable variation in terms of coverage and conditions of reimbursement related to on- and off-label uses of mAbs. Our results point to four major challenges facing mAb developers, health care providers, Medicare beneficiaries, payers and policymakers. These include administrative price controls, coverage variation, projected shift from physician- to self-administered mAbs, and comparative effectiveness. We suggest more systematic use of "coverage with evidence development" as a means of optimally addressing these challenges.
Cohen
Joshua
J
Tufts Center for the Study of Drug Development (CSDD), Boston, Massachusetts 02111, USA. joshua.cohen@tufts.edu
Wilson
Andrew
A
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use*; D017277:Drug Approval / Q000191:economics; D004345:Drug Industry / Q000191:economics; D004363:Drug Utilization / Q000191:economics; D033161:Government Regulation; D006297:Health Services Accessibility / Q000191:economics*; D006801:Humans; D006278:Medicare / Q000191:economics*; D056687:Off-Label Use; D011050:Policy Making; D014481:United States
D000911:Antibodies, Monoclonal